- Home
- PGNY vs MLTX Comparison
PGNY vs MLTX Comparison
Compare PGNY & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGNY | MLTX |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PGNY | MLTX |
|---|---|---|
| Price | $24.85 | $11.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $34.42 | $28.54 |
| AVG Volume (30 Days) | 892.2K | ★ 1.6M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.04 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $1,288,661,000.00 | N/A |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $39.40 | ★ N/A |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $16.10 | $7.50 |
| 52 Week High | $33.07 | $23.29 |
Technical Indicators
Market Signals| Indicator | PGNY | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.28 | 31.71 |
| Support Level | $25.16 | $11.06 |
| Resistance Level | $26.51 | $19.24 |
| Average True Range (ATR) | 0.66 | 0.61 |
| MACD | -0.14 | 0.04 |
| Stochastic Oscillator | 24.38 | 14.63 |
Price Performance
Historical ComparisonAbout PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.